Results 11 to 20 of about 1,677,629 (133)

Once-Nightly Sodium Oxybate Meets American Academy of Sleep Medicine Criteria for Treatment of Narcolepsy. [PDF]

J Sleep Res
Data from the REST-ON trial were not available before the 2021 American Academy of Sleep Medicine (AASM) clinical practice guideline update, which included a literature review through August 2020. This post hoc analysis from REST-ON assessed participants
Ortiz LE, Morse AM, Thorpy MJ, Kushida CA, Harsh J, Roth T, Gudeman J, Dauvilliers Y.   +7 more
europepmc   +6 more sources

Weight Loss With Once-nightly Sodium Oxybate for the Treatment of Narcolepsy: Analysis From the Phase III Randomized study Evaluating the efficacy and SafeTy of a ONce nightly formulation of sodium oxybate (REST-ON) Trial

Clinical Therapeutics
PURPOSE: Individuals with narcolepsy are more likely to be obese than the general population. Changes in weight-related measures with extended-release, once-nightly sodium oxybate (ON-SXB) and characteristics of participants with ≥ 5% weight loss were ...
Richard Bogan, Thomas Roth, Yves Dauvilliers   +2 more
exaly   +5 more sources

Preferences for Attributes of Sodium Oxybate Treatment: A Discrete Choice Experiment in Patients with Narcolepsy [PDF]

Patient Preference and Adherence, 2022
Jordan Dubow,1 Alon Y Avidan,2 Bruce Corser,3 Amod Athavale,4 David Seiden,1 Clete Kushida5 1Avadel Pharmaceuticals, Chesterfield, MO, USA; 2Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; 3Sleep Management ...
Dubow J, Avidan AY, Corser B, Athavale A, Seiden D, Kushida C   +5 more
doaj   +2 more sources

Practical Guidance for Initiation and Management of Patients on Once-Nightly Sodium Oxybate for Narcolepsy Treatment: Modified Delphi Panel Consensus Recommendations [PDF]

Neurology and Therapy
Introduction Despite its strong recommendation for treatment of excessive daytime sleepiness (EDS), cataplexy, and disease severity associated with narcolepsy by the American Academy of Sleep Medicine, sodium oxybate (SXB) remains underutilized.
Monique Mulvany, Ellen Wermter, Maggie Lavender, Heidy Merius, Cecile Martin, Amber Burns, Jamie Simmons   +6 more
doaj   +2 more sources

Long-Term Treatment of Narcolepsy and Idiopathic Hypersomnia with Low-Sodium Oxybate

Nature and Science of Sleep, 2023
Logan D Schneider,1 Anne Marie Morse,2 Michael J Strunc,3 Joyce K Lee-Iannotti,4 Richard K Bogan5 1Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA; 2Janet Weis Children’s Hospital, Geisinger ...
Schneider LD, Morse AM, Strunc MJ, Lee-Iannotti JK, Bogan RK   +4 more
doaj   +3 more sources

Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial. [PDF]

CNS Drugs, 2022
BACKGROUND: Sodium oxybate has been recognized as a gold standard for the treatment of disrupted nighttime sleep due to narcolepsy. Its short half-life and immediate-release formulation require patients to awaken 2.5-4 h after their bedtime dose to take ...
Roth T, Dauvilliers Y, Thorpy MJ, Kushida C, Corser BC, Bogan R, Rosenberg R, Dubow J, Seiden D.   +8 more
europepmc   +4 more sources

Evidence of Accidental Dosing Errors with Immediate-Release Sodium Oxybate: Data from the US Food and Drug Administration Adverse Event Reporting System

Drugs - Real World Outcomes, 2023
Introduction Sodium oxybate has been approved by the US Food and Drug Administration (FDA) to treat narcolepsy for 20 years; however, the only available products have been immediate-release (IR) formulations given twice nightly—once at bedtime and a ...
Jennifer Gudeman, Danielle Burroughs
doaj   +2 more sources

Once-nightly sodium oxybate (FT218) in the treatment of narcolepsy: a letter to the editor commenting on the recent publication by C. Kushida et al. [PDF]

Sleep, 2022
FT218 is an investigational, once-nightly, modified-release formulation of sodium oxybate (SO). SO effectively treats excessive daytime sleepiness and cataplexy in patients with narcolepsy. Current approved SO formulations, at effective doses of 6, 7.5, and 9 g, require twice-nightly divided dosing, with the first dose taken at bedtime and the second 2.
Skobieranda F, Candler S, Macfadden W.
europepmc   +6 more sources

Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial [PDF]

Sleep, 2023
Richard Bogan, Thomas Roth, Yves Dauvilliers   +2 more
exaly   +2 more sources

Response to: Once-nightly sodium oxybate (FT218) in the treatment of narcolepsy: a letter to the editor commenting on the recent publication by C. Kushida et al. [PDF]

Sleep, 2022
Abstract Introduction Sodium oxybate is an effective treatment for excessive daytime sleepiness and cataplexy in patients with narcolepsy. The approved formulation requires twice-nightly dosing: at bedtime and 2.5 - 4 hours later, which results in two distinct Cmax’s.
Kushida CA, Roth T, Shapiro CM, Roy A, Rosenberg R, Ajayi AO, Seiden D, Gudeman J.   +7 more
europepmc   +3 more sources